Synjardy XR (Empagliflozin/Metformin HCl) Patent Expiration, LOE Window & CMS Spending

Synjardy XR (Empagliflozin/Metformin HCl) by Boehringer Ingelheim: FDA Orange Book core substance LOE 2029-02-01 (last listed 2034-12-11), 0 AB generics, $361.0M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBoehringer Ingelheim
FDA Application & PathwayN208658 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2029-02-01
Last Listed Patent or Exclusivity Date2034-12-11
Orange Book Patents (*PED Extensions)25 patents (11 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$361.0M
2024 Medicare Part D Spend$320.7M
2024 Medicaid Spend$40.3M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.